EA201990903A1 - METHOD FOR REDUCING PROTEINURIA IN A HUMAN SUFFERING FROM IMMUNOGLOBULIN AND NEPHROPATHY - Google Patents

METHOD FOR REDUCING PROTEINURIA IN A HUMAN SUFFERING FROM IMMUNOGLOBULIN AND NEPHROPATHY

Info

Publication number
EA201990903A1
EA201990903A1 EA201990903A EA201990903A EA201990903A1 EA 201990903 A1 EA201990903 A1 EA 201990903A1 EA 201990903 A EA201990903 A EA 201990903A EA 201990903 A EA201990903 A EA 201990903A EA 201990903 A1 EA201990903 A1 EA 201990903A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nephropathy
immunoglobulin
human suffering
reducing proteinuria
masp
Prior art date
Application number
EA201990903A
Other languages
Russian (ru)
Inventor
Найджел Джон Бранскилл
Грегори А. Демопулос
Том Дадлер
Ханс-Вильхельм Швебле
Original Assignee
Юниверсити Оф Лестер
Омерос Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Лестер, Омерос Корпорейшн filed Critical Юниверсити Оф Лестер
Priority claimed from PCT/US2017/056386 external-priority patent/WO2018071701A1/en
Publication of EA201990903A1 publication Critical patent/EA201990903A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

В одном из аспектов изобретение относится к способам уменьшения протеинурии у человека, страдающего или подверженного риску развития иммуноглобулин A нефропатии (IgAN). Способы включают этап введения нуждающемуся в этом субъекту количества ингибирующего MASP-2 антитела, эффективного для подавления MASP-2-зависимой активации комплемента.In one aspect, the invention relates to methods for reducing proteinuria in a person suffering from or at risk of developing immunoglobulin A nephropathy (IgAN). The methods include the step of administering to a subject in need thereof an amount of a MASP-2 inhibitory antibody effective to suppress MASP-2 dependent complement activation.

EA201990903A 2017-06-30 2017-10-12 METHOD FOR REDUCING PROTEINURIA IN A HUMAN SUFFERING FROM IMMUNOGLOBULIN AND NEPHROPATHY EA201990903A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527926P 2017-06-30 2017-06-30
PCT/US2017/056386 WO2018071701A1 (en) 2016-10-13 2017-10-12 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Publications (1)

Publication Number Publication Date
EA201990903A1 true EA201990903A1 (en) 2020-01-27

Family

ID=69374505

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990903A EA201990903A1 (en) 2017-06-30 2017-10-12 METHOD FOR REDUCING PROTEINURIA IN A HUMAN SUFFERING FROM IMMUNOGLOBULIN AND NEPHROPATHY

Country Status (1)

Country Link
EA (1) EA201990903A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115192563A (en) * 2022-05-09 2022-10-18 北京大学第一医院 Use of C3a/C3aR pathway antagonists for the treatment of primary membranous nephropathy

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115192563A (en) * 2022-05-09 2022-10-18 北京大学第一医院 Use of C3a/C3aR pathway antagonists for the treatment of primary membranous nephropathy
CN115192563B (en) * 2022-05-09 2023-10-13 北京大学第一医院 Use of C3a/C3aR pathway antagonists for the treatment of primary membranous nephropathy

Similar Documents

Publication Publication Date Title
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
CO2017013356A2 (en) Factor xi antibodies
PH12018502046A1 (en) Methods for inhibiting angiogenesis in a subject in need thereof
DOP2020000245A (en) IL-11 ANTIBODIES
EA201790192A1 (en) WAY TO REDUCE Fc-RECEPTOR BINDING OF SERUM IgG MOLECULES IN SUBJECT
NZ738008A (en) Tigit-binding agents and uses thereof
DK3858977T3 (en) STRAIN FOR THE PREVENTION AND TREATMENT OF METABOLISM DISEASES, AND THE USE THEREOF
EA201692394A1 (en) ANTIBODIES AND ANTIGENS-BINDING FRAGMENTS, WHICH SPECIFICALLY CONNECT WITH THE PROUCH OF TAU ASSOCIATED WITH MICROTUBULES
EA201891570A1 (en) METHOD OF SUPPORTING FIBROSIS IN NECESSARY IN THIS SUBJECT
GB201813459D0 (en) Transaction system and method of operation thereof
MA52962A (en) CANCER TREATMENT METHODS WITH BISPECIFIC ANTI-CD3XMUC16 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
EA201990778A1 (en) ANTI-IL-33 ANTIBODIES AND THEIR APPLICATION
MX2020008122A (en) Anti-pd-1 antibodies.
BR112021008873A8 (en) FORMULATION
EA201890340A1 (en) MONOCLONAL ANTIBODY-INHIBITOR OF FACTOR XIIA
BR112017002433A2 (en) anti-amide antibodies
MX2021002301A (en) Anti-cd3 antibody folate bioconjugates and their uses.
NZ733454A (en) Treatment of autoimmune disorders with cd154 antibodies
PH12019500711A1 (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
BR112018014762A2 (en) method of treating (early) alzheimer's disease
EP4011919A3 (en) Relaxin immunoglobulin fusion proteins and methods of use
EA202090260A1 (en) MEANS AND METHODS FOR HUMAN AAV GENOTHERAPY
EA201990903A1 (en) METHOD FOR REDUCING PROTEINURIA IN A HUMAN SUFFERING FROM IMMUNOGLOBULIN AND NEPHROPATHY
DK3630177T3 (en) TREATMENT PARADIGM FOR AN ANTI-CD19 ANTIBODY AND VENETOCLAX COMBINATION THERAPY
CO2018012652A2 (en) Matured anti-fcrn antibodies of humanized affinity